Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND: Anakinra pharmacokinetics and pharmacodynamics were investigated in children and adolescents treated for systemic-onset juvenile idiopathic arthritis (SJIA) and autoinflammatory syndromes. METHODS: Anakinra was given subcutaneously at doses between 2 and 10 mg/kg (maximum 100 mg) per day. Anakinra concentrations were recorded in patients, as well as C-reactive protein (CRP) levels, on different occasions. The data were fitted to a pharmacokinetic-pharmacodynamic model via a population approach using Monolix. RESULTS: A total of 87 children and adolescents, 8 months to 21 years old, were available for pharmacokinetic evaluation. A one compartment model with linear absorption and elimination described the pharmacokinetics. Taking into account bodyweight to explain variations in apparent clearance (CL/F) and distribution volume (V/F) significantly reduced the associated between-subject and between-occasion variabilities. The final estimates were 6.24 L/h/70 kg and 65.2 L/70 kg for CL/F and V/F respectively. A mixture pharmacodynamic model described the CRP level change during anakinra treatment for the SJIA patients with 2 subpopulations, patients with high baseline and large CRP decrease and patients with low baseline and small CRP decrease followed by a re-increase in CRP levels. There was no significant effect of the combined anti-inflammatory treatment. The proportion of patients for which the development of a resistance to treatment was significant was 62% and the corresponding time was approximately 60 days. CONCLUSIONS: Based on effects in SJIA, a prospective dosage adjustment was proposed based on a 0.4 mg/L Css target in order to obtain a CRP decrease to 10 mg/L or below.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Recommendations for the management of autoinflammatory diseases
ter Haar, N. M., Oswald, M., Jeyaratnam, J., Anton, J., Barron, K. S., Brogan, P. A., Cantarini, L., Galeotti, C., Grateau, G., Hentgen, V., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207546 · Cited by 278
Self-citationFebrile infection‐related epilepsy syndrome treated with anakinra
Kenney‐Jung, D. L., Vezzani, A., Kahoud, R. J., LaFrance‐Corey, R. G., Ho, M., Muskardin, T. W., Wirrell, E. C., Howe, C. L., & Payne, E. T. (2016) · Annals of Neurology · doi:10.1002/ana.24806 · Cited by 265
Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis?
Nigrovic, P. A. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38615 · Cited by 217
“) Pharmacokinetic studies of anakinra suggest that smaller children require higher doses per kilogram of body weight to achieve equivalent drug levels, potentially explaining why remission was less often attained in young patients at conventional doses of 1–2 mg/kg/day (12,36,37).”
BackgroundSystemic Juvenile Idiopathic Arthritis
Lee, J. J. Y., & Schneider, R. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.04.005 · Cited by 166
McClatchy, J., Strogantsev, R., Wolfe, E., Lin, H. Y., Mohammadhosseini, M., Davis, B. A., Eden, C., Goldman, D., Fleming, W. H., Conley, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43697-y · Cited by 95
“IL1 signaling blockade is a promising therapeutic approach to treat in fl ammatory diseases 45 , cancer 12 – 14, 54 , and cardiovascular”
Metadata
- Authors
- Urien, S., Bardin, C., Bader-Meunier, B., Mouy, R., Compeyrot-Lacassagne, S., Foissac, F., Florkin, B., Wouters, C., Neven, B., Treluyer, J.-M., & Quartier, P.
- Venue
- BMC Pharmacology and Toxicology
- Published
- 2013-08-05
- Volume
- 14
- Issue
- 1
- Pages
- 40-40
- ISSN
- 2050-6511 (ISSN-L)
- OpenAlex
- W1980376496
- Cited by
- 59
- References
- 0
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. https://app.cochat.ai/papers/10.1186/2050-6511-14-40
- The paper
- Urien, S., Bardin, C., Bader-Meunier, B., Mouy, R., Compeyrot-Lacassagne, S., Foissac, F., Florkin, B., Wouters, C., Neven, B., Treluyer, J.-M., & Quartier, P. (2013). Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC Pharmacology and Toxicology. https://doi.org/10.1186/2050-6511-14-40
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.